How many doses per year for lenacapavir?

Two annual injections provide nearly 100% protection against HIV infection.

Why is $40 the target price?

$40 is considered a sustainable cost level for low- and middle-income countries to adopt the drug.

What is compulsory licensing?

A WTO flexibilities allowing governments to authorize generic production without patent holder consent for public health.

Why is MSF criticizing Gilead?

Due to high pricing and supply restrictions preventing at-risk populations from accessing this innovative drug.

Which countries are the main focus of the campaign?

Malawi, Mozambique, Brazil, and other high-risk, low-access countries.

AI News NQ Analysis

HIV Prevention Drug: 'Everyone Should Access It for $40 a Year' – Doctors Without Borders Launches Campaign Against U.S. Pharmaceutical Company

Key facts

HIV Prevention Drug: 'Everyone Should Access It for $40 a Year' – Doctors Without Borders Launches Campaign Against U.S. Pharmaceutical Company
Doctors Without Borders (MSF) has launched a campaign urging U.S.-based pharmaceutical company Gilead Sciences to make the highly effective HIV prevention drug lenacapavir rapidly and widely available worldwide. MSF demands the annual two-dose regimen be accessible for under $40 in all regions, especially in low- and middle-income countries.
Source: PR TIMES
Date: Thu Jun 18 2026 03:28:05 GMT+0900 (Japan Standard Time)

Direct answer

Doctors Without Borders (MSF) has launched a campaign urging U.S.-based pharmaceutical company Gilead Sciences to make the highly effective HIV prevention drug lenacapavir rapidly and widely available worldwide. MSF demands the annual two-dose regimen be accessible for under $40 in all regions, especially in low- and middle-income countries.

Citation: HIV Prevention Drug: 'Everyone Should Access It for $40 a Year' – Doctors Without Borders Launches Campaign Against U.S. Pharmaceutical Company (Thu Jun 18 2026 03:28:05 GMT+0900 (Japan Standard Time)), PR TIMES
Source: PR TIMES
Date: Thu Jun 18 2026 03:28:05 GMT+0900 (Japan Standard Time)

AI Summary (NQ-processed)

Doctors Without Borders (MSF) has launched a campaign urging U.S.-based pharmaceutical company Gilead Sciences to make the highly effective HIV prevention drug lenacapavir rapidly and widely available worldwide. MSF demands the annual two-dose regimen be accessible for under $40 in all regions, especially in low- and middle-income countries.

AI Analysis

Frequently Asked Questions

Q: How many doses per year for lenacapavir?: A: Two annual injections provide nearly 100% protection against HIV infection.
Q: Why is $40 the target price?: A: $40 is considered a sustainable cost level for low- and middle-income countries to adopt the drug.
Q: What is compulsory licensing?: A: A WTO flexibilities allowing governments to authorize generic production without patent holder consent for public health.
Q: Why is MSF criticizing Gilead?: A: Due to high pricing and supply restrictions preventing at-risk populations from accessing this innovative drug.
Q: Which countries are the main focus of the campaign?: A: Malawi, Mozambique, Brazil, and other high-risk, low-access countries.